Hostname: page-component-77c89778f8-swr86 Total loading time: 0 Render date: 2024-07-19T22:04:23.157Z Has data issue: false hasContentIssue false
  • English
  • Français

Ergotamine and Methysergide Abuse in Patients with Migraine

Published online by Cambridge University Press:  29 January 2018

R. N. Lucas  and
W. Falkowski
R. N. Lucas
Affiliation:
The Bethlem Royal and Maudsley Hospital, London S.E.5
W. Falkowski
Affiliation:
The Bethlem Royal and Maudsley Hospital, London S.E.5
Get access Rights & Permissions [Opens in a new window]

Extract

Ergotamine preparations are extensively used in the treatment of migraine. Although not widely appreciated, there have been reports in the literature of ergotamine abuse, related to the development of tolerance and withdrawal headaches, which result in a steadily increasing consumption of the drug (Wolfson and Graham, 1949; Peters and Horton, 1951; Friedman et al., 1955). It is important clinically to recognize this condition, as ergotamine can have dangerous vascular side-effects (Byrne-Quinn, 1964; Cranley et al., 1963; Young and Humphries, 1961).

Type
Research Article
Information
The British Journal of Psychiatry , Volume 122 , Issue 567 , February 1973 , pp. 199 - 203
Copyright
Copyright © Royal College of Psychiatrists, 1973 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Berde, B., Cerletti, A., Dengler, H. J., and Zoglio, M. A. (1969). ‘Studies of the interaction between ergot alkaloids and xanthine derivatives’, in Background to Migraine, 3rd Migraine Symposium (ed. A. L. Cochrane). Heinemann.Google Scholar
Byrne-Quinn, E. (1964). ‘Prolonged arteriospasm after overdose of oral ergotamine tartrate in migraine.’ British Medical Journal, ii, 552–3.Google Scholar
Cran ley, J. J., Krause, R. J., Strasser, E. S., and Hafner, C. D. (1963). ‘Impending gangrene of four extremities secondary to ergotism.’ New England Journal of Medicine, 269, 727–29.Google Scholar
Curran, D. A., and Lance, J. W. (1964). ‘Clinical trial of methysergide and other preparations in the management of migraine.’ Journal of Neurology, Neurosurgery Nand Psychiatry, 27, 463–9.Google ScholarPubMed
Dalessio, D. J., Curry, W. A., Goodell, H., and Wolff, H. G. (1961). ‘Studies on headache. The mode of action of UML-491 and its relevance to the nature of vascular headache of the migraine type.’ Archives of Neurology, 4, 235–40.CrossRefGoogle Scholar
De La Lande, I. S., Cannell, V. A., and Waterson, J. G. (1966). ‘The interaction of serotonin and noradrenaline on the perfused artery.’ British Journal of Pharmacology and Chemotherapy, 28, 255–72.CrossRefGoogle ScholarPubMed
Friedman, A. P., Brazil, P., and Von Storch, T. J. C. (1955). ‘Ergotamine tolerance in patients with migraine.’ Journal of American Medical Association, 157, 881–4.CrossRefGoogle ScholarPubMed
Friedman, A. P. and Elkind, A. H. (1963). ‘Appraisal of methysergide in treatment of vascular headaches of migraine type.’ Journal of American Medical Association, 184, 125–8.Google Scholar
Friedman, A. P. and Elkind, A. H. (1968). ‘The migraine syndrome.’ Bulletin of the New York Academy of Medicine, 44, 45–62.Google ScholarPubMed
Friedman, A. P. and Elkind, A. H. (1969). ‘The infinite variety of migraine’, in Background to Migraine, 3rd Migraine Symposium (ed. A. L. Cochrane). Heinemann.Google Scholar
Graham, J. R. (1964). ‘Methysergide for prevention of headache.’ New England Journal of Medicine, 270, 67–72.Google Scholar
Graham, J. R., Suby, H. I., Le Compte, P. R., and Sadowsky, N. L. (1966). ‘Fibrotic disorders associated with methysergide therapy for headaches.’ New England Journal of Mediane, 274, 359–68.Google Scholar
Lance, J. W., Anthony, M., and Somerville, B. (1970). ‘Comparative trial of serotonin antagonists in the management of migraine.’ British Medical Journal, ii, 327–30.Google Scholar
Peters, G. A., and Horton, B. T. (1951). ‘Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects.’ Proceedings of Mayo Clinic, 26, 153–61.Google Scholar
Goodman, L. S., and Gilman, A. (1970). Ed. The Pharmacological Basis of Therapeutics, 4th edition. Macmillan.Google Scholar
Waters, W. E. (1970). ‘Controlled clinical trial of ergotamine tartrate.’ British Medical Journal, ii, 325–7.Google Scholar
Wolff, H. G. (1963). Headache and Other Pain. 2nd edition. Oxford University Press.Google Scholar
Wolfson, W. Q., and Graham, J. R. (1949). ‘Development of tolerance to ergot alkaloids in a patient with unusually severe migraine.’ New England Journal of Mediane, 241, 296–8.Google Scholar
Young, J. R., and Humphries, A. W. (1961). ‘Severe arteriospasm after use of ergotamine tartrate suppositories—report of a case.’ Journal of American Medical Association, 175, 1141–5.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.